Ad
CLLS Short Information Cellectis S.A.
home / stock / clls / clls short
Short Information | Cellectis S.A. (NASDAQ:CLLS)
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 728,935 |
| Total Actual Volume | 4,231,101 |
| Short Trends | |
|---|---|
| Cover Days | 20 |
| Short Days | 0 |
| No Change Days | 0 |
| Averages | |
|---|---|
| Average Short Volume | 36,447 |
| Average Short Percentage | 14.63% |
Is there a CLLS Short Squeeze or Breakout about to happen?
See the CLLS Short Analysis for free Sign up or Login
Powered by Squeeze Report
CLLS Twenty Trading Day's Volume to Short Volume Chart
CLLS Twenty Trading Day Price Chart
CLLS Short Data Results Days
| Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 01-14-2025 | $1.74 | $1.68 | $1.7999 | $1.66 | 161,208 | 11,065 | 6.86% |
| 01-13-2025 | $1.83 | $1.68 | $1.8885 | $1.65 | 263,417 | 41,064 | 15.59% |
| 01-10-2025 | $1.93 | $1.85 | $1.93 | $1.82 | 125,461 | 19,121 | 15.24% |
| 01-08-2025 | $2.03 | $1.93 | $2.03 | $1.88 | 210,196 | 36,569 | 17.4% |
| 01-07-2025 | $2.19 | $2.1 | $2.2185 | $2.09 | 399,567 | 61,060 | 15.28% |
| 01-06-2025 | $1.79 | $2.13 | $2.23 | $1.76 | 826,154 | 161,547 | 19.55% |
| 01-03-2025 | $1.8 | $1.675 | $1.8 | $1.66 | 325,995 | 56,522 | 17.34% |
| 01-02-2025 | $1.78 | $1.81 | $1.8401 | $1.7716 | 100,542 | 23,508 | 23.38% |
| 12-31-2024 | $1.88 | $1.8 | $1.95 | $1.77 | 384,383 | 102,324 | 26.62% |
| 12-30-2024 | $1.45 | $1.82 | $1.82 | $1.45 | 797,203 | 130,355 | 16.35% |
| 12-27-2024 | $1.51 | $1.41 | $1.59 | $1.41 | 127,160 | 21,477 | 16.89% |
| 12-26-2024 | $1.56 | $1.51 | $1.59 | $1.51 | 94,180 | 5,191 | 5.51% |
| 12-24-2024 | $1.57 | $1.56 | $1.61 | $1.53 | 7,303 | 244 | 3.34% |
| 12-23-2024 | $1.59 | $1.5719 | $1.6201 | $1.5719 | 20,375 | 1,423 | 6.98% |
| 12-20-2024 | $1.58 | $1.64 | $1.64 | $1.53 | 87,886 | 7,482 | 8.51% |
| 12-19-2024 | $1.62 | $1.59 | $1.62 | $1.5787 | 73,884 | 13,936 | 18.86% |
| 12-18-2024 | $1.69 | $1.63 | $1.7164 | $1.6046 | 41,020 | 2,408 | 5.87% |
| 12-17-2024 | $1.718 | $1.705 | $1.78 | $1.6901 | 63,166 | 12,896 | 20.42% |
| 12-16-2024 | $1.76 | $1.73 | $1.78 | $1.7 | 55,422 | 4,904 | 8.85% |
| 12-13-2024 | $1.82 | $1.76 | $1.87 | $1.74 | 66,579 | 15,839 | 23.79% |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
-
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
-
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...